(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 May 2010 (27.05.2010)

PCT

(10) International Publication Number
WO 2010/059788 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:
PCT/US2009/065085

(22) International Filing Date:
19 November 2009 (19.11.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/116,427 20 November 2008 (20.11.2008) US

(71) Applicants *(for all designated States except US)*: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DOTSON, Jennafer** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **HEFFRON, Tim** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **OLIVERO, Alan G.** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **SUTHERLIN, Daniel P.** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **STABEN, Steven** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **WANG, Shumei** [CA/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **ZHU, Bing-Yan** [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). **CHUCKOWREE, Irina S.** [MU/CH]; c/o F. HOFFMANN-LA ROCHE AG, Grenzacherstrasse 124, CH-4070 Basel (CH). **FOLKES, Adrian J.** [GB/CH]; c/o F. HOFFMANN-LA ROCHE AG, Grenzacherstrasse 124, CH-4070 Basel (CH). **WAN, Nan Chi** [GB/CH]; c/o F. HOFFMANN-LA ROCHE AG, Grenzacherstrasse 124, CH-4070 Basel (CH).


(74) Agents: **ANDRUS, Alex** et al.; Genentech, Inc., 1 DNA Way, MS 49, South San Francisco, California 94080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE



(I)

(57) Abstract: Compounds of Formula (I), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer or inflammation mediated by lipid kinases. Methods of using compounds of Formula (I) for *in vitro, in situ*, and *in vivo* diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

WO 2010/059788 A1

Published:

— *with international search report (Art. 21(3))*